Options activity in Vera Therapeutics Inc. (NASDAQ: VERA) surged on Tuesday, with total volume reaching 13,224 contracts as investors positioned for a bullish call spread targeting September expirations.
The most significant trade involved a 6,022-by-6,022 contract call spread using the September 18, 2026 $35 and $45 strikes, accounting for more than 90% of total options volume. Call volume dominated, with 12,811 contracts traded compared with 413 puts. Vera’s stock was last quoted at $34.44, up $0.72, or 2.12%, in midday trading on August 25.
Open interest in the $35 calls rose to 4,797, while the $45 calls stood at 1,445. The 3-month volatility for Vera’s options declined by 3.86 points to 71.99%, while the 3-month 90/110 skew fell by 4.10 points to -0.65, reflecting shifting market expectations.
Analyst targets for Vera remain elevated, with the average price target at $77.14 and some upgrades reaching as high as $100. Recent corporate developments, including FDA approvals and analyst upgrades, as well as insider share sales by the CEO, have contributed to heightened trading interest in the biopharmaceutical company’s options.
